United Therapeutics (UTHR) Preferred Stock Liabilities (2012 - 2019)

United Therapeutics has reported Preferred Stock Liabilities for 8 years, with the latest figure at $8.4 million in Q2 2019.

• Quarterly Preferred Stock Liabilities fell 56.25% year-over-year to $8.4 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $8.4 million (down 56.25% YoY) and the FY2018 annual result came in at $19.2 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities fell to $8.4 million in Q2 2019 per UTHR's latest filing, from $19.2 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $20.4 million in Q1 2015 and troughed at $8.4 million in Q2 2019.
• A 5-year average of $15.2 million and a median of $16.1 million in 2015 frame the typical range for Preferred Stock Liabilities.
• The sharpest annual moves came in 2015 and 2017: Preferred Stock Liabilities slumped 66.6% in 2015, then jumped 76.15% in 2017.
• Over 5 years, Preferred Stock Liabilities stood at $11.1 million in 2015, then retreated by 1.8% to $10.9 million in 2016, then surged by 76.15% to $19.2 million in 2017, then changed by 0.0% to $19.2 million in 2018, then tumbled by 56.25% to $8.4 million in 2019.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $8.4 million, $19.2 million, and $19.2 million for Q2 2019, Q1 2019, and Q4 2018 respectively.